<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03615404</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00092868</org_study_id>
    <nct_id>NCT03615404</nct_id>
  </id_info>
  <brief_title>Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma</brief_title>
  <acronym>ATTAC-P</acronym>
  <official_title>A Phase 1 Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary Archer Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility and safety of administering CMV&#xD;
      RNA-pulsed dendritic cells (DCs), also known as CMV-DCs, to children and young adults up to&#xD;
      35 years old with nWHO Grade IV glioma, recurrent malignant glioma, or recurrent&#xD;
      medulloblastoma. Evidence for efficacy will also be sought. This will be a phase 1 study&#xD;
      evaluating CMV-DC administration with tetanus toxoid (Td) preconditioning and Granulocyte&#xD;
      Macrophage-Colony Stimulating Factor (GM-CSF) adjuvant in children and young adults up to 35&#xD;
      years old with WHO grade IV glioma, recurrent malignant glioma, or recurrent medulloblastoma.&#xD;
      This safety study will enroll a maximum of 10 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in this study will undergo a leukapheresis procedure in which blood is collected&#xD;
      into a machine that removes white blood cells and then returns the remainder of the blood&#xD;
      back to the individual. The white blood cells removed from the blood are used to make the&#xD;
      participant's study vaccine. Newly diagnosed patients will undergo standard radiation therapy&#xD;
      (RT) with or without temozolomide after leukapheresis. If a patient has been diagnosed with a&#xD;
      Grade IV glioma or recurrence of either malignant glioma or medulloblastoma, the study doctor&#xD;
      may recommend &quot;bridge therapy&quot; after leukapheresis. Bridge therapy is approved or standard&#xD;
      therapy for the tumor intended to bridge the time without the study drugs, dose-intensified&#xD;
      temozolomide (DI-TMZ) or CMV-DC vaccine. All participants will undergo a cycle of&#xD;
      &quot;dose-intensified&quot; temozolomide. Participants will receive Td pre-conditioning given as a&#xD;
      shot in the right leg, six to 24 hours before receiving their 1st vaccine, which is also&#xD;
      given as shots in the legs. If more than one vaccine is made, vaccines #2 and #3 will occur&#xD;
      at 2-week intervals after the 1st vaccine. After the 3rd vaccine, there will be 4 weeks&#xD;
      between vaccines for as many vaccines as the study team can prepare from the participant's&#xD;
      leukapheresis.&#xD;
&#xD;
      Please note data collection will continue to occur outside of the defined primary outcomes&#xD;
      for 2 exploratory objectives- describing changes in T cell response to CMV-DC vaccination and&#xD;
      describing overall and progression-free survival of patients enrolled on the study. The&#xD;
      percent change in pp65-specific T cell responses will be calculated from a pre-chemotherapy&#xD;
      baseline, post-chemotherapy baseline, 1 week after Vaccine #3, and 1 week after final&#xD;
      vaccine. Progression-free survival is defined as the time between starting DI TMZ and disease&#xD;
      progression. Patients will be followed for overall survival for up to 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2018</start_date>
  <completion_date type="Actual">July 2, 2020</completion_date>
  <primary_completion_date type="Actual">November 19, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients for Whom 3 or More Vaccines Can be Made</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients for whom three or more vaccines can be generated from the pre-treatment leukapheresis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Patients Who Experience Unacceptable Toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients who experience unacceptable toxicity from CMV-DC administration</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Malignant Glioma</condition>
  <condition>Medulloblastoma Recurrent</condition>
  <condition>Pediatric Glioblastoma Multiforme</condition>
  <condition>Pediatric Brain Tumor, Recurrent</condition>
  <condition>Pediatric Brain Tumor</condition>
  <arm_group>
    <arm_group_label>CMV-DCs with GM-CSF and Td (tetanus toxoid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CMV-DCs with GM-CSF</intervention_name>
    <description>CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.</description>
    <arm_group_label>CMV-DCs with GM-CSF and Td (tetanus toxoid)</arm_group_label>
    <other_name>pp65-flLAMP DC with GM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Td (tetanus toxoid)</intervention_name>
    <description>Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.</description>
    <arm_group_label>CMV-DCs with GM-CSF and Td (tetanus toxoid)</arm_group_label>
    <other_name>Tetanus and Diphtheria Toxoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age requirements:&#xD;
&#xD;
               1. ≤ 35 years for patients with grade IV glioma or recurrent World Health&#xD;
                  Organization (WHO) grade IV glioma&#xD;
&#xD;
               2. 3-35 years old for patients with recurrent medulloblastoma&#xD;
&#xD;
          2. Newly diagnosed or recurrent WHO grade IV glioma, recurrent WHO grade III glioma, or&#xD;
             recurrent medulloblastoma (multifocal/disseminated disease is eligible, at the&#xD;
             discretion of the PI)&#xD;
&#xD;
          3. Patients with WHO grade IV glioma who received surgery and radiation are eligible even&#xD;
             without recurrence or progression&#xD;
&#xD;
          4. Patients must have recovered from all previous treatments including chemotherapy,&#xD;
             radiation therapy, surgery, and other immunotherapies, etc.&#xD;
&#xD;
             a. If the patient was receiving bevacizumab at the time of enrollment, the treating&#xD;
             oncologist has the discretion of administering and adjusting bevacizumab 10 mg/kg&#xD;
             every 14 days. The rationale for continuing patients on bevacizumab is to prevent&#xD;
             rebound cerebral edema commonly seen after stopping this agent.&#xD;
&#xD;
          5. Laboratory Studies:&#xD;
&#xD;
               1. Platelets ≥ 100,000 cells/mm3&#xD;
&#xD;
               2. Creatinine ≤ 1.2 x upper limit of normal (ULN)&#xD;
&#xD;
               3. Total bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase&#xD;
                  (ALT), alkaline phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
               4. Neutrophil count ≥ 1000 cells/mm3&#xD;
&#xD;
               5. Hemoglobin ≥ 9 g/dl prior to biopsy (can be transfused)&#xD;
&#xD;
          6. Able to undergo brain MRI with and without contrast&#xD;
&#xD;
          7. Karnofsky Performance Status (KPS) ≥ 70 or Lansky Performance Status (LPS) ≥ 70&#xD;
&#xD;
          8. A signed informed consent form approved by the Institutional Review Board (IRB) will&#xD;
             be required for patient enrollment into the study. Patients (if 18 years old or older)&#xD;
             or their parent(s) or guardian(s) (if younger than 18 years old) must be able to read&#xD;
             and understand the informed consent document and must sign the informed consent&#xD;
             indicating that they are aware of the investigational nature of this study.&#xD;
&#xD;
          9. For females of childbearing potential, negative serum pregnancy test within 48 hours&#xD;
             of leukapheresis&#xD;
&#xD;
         10. Females of childbearing potential must be willing to use acceptable contraceptive&#xD;
             method to avoid pregnancy throughout the study and for at least 24 weeks after the&#xD;
             last dose of study drug&#xD;
&#xD;
         11. Males with female partners of childbearing potential must agree to practice adequate&#xD;
             contraceptive methods throughout the study and should avoid conceiving children for 24&#xD;
             weeks following the last dose of study drug&#xD;
&#xD;
         12. Newly diagnosed WHO grade IV glioma patients only: must be expected to complete&#xD;
             standard of care radiation (minimum ~54 Gray)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease&#xD;
             free for ≥ 3 years. (For example, carcinoma in situ of the breast, oral cavity, and&#xD;
             cervix are all permissible)&#xD;
&#xD;
          2. Disease outside of the central nervous system (CNS)&#xD;
&#xD;
          3. Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C seropositive&#xD;
&#xD;
          4. Known active infection requiring intravenous (IV) antibiotics or active&#xD;
             immunosuppressive disease&#xD;
&#xD;
          5. Severe, active co-morbidity, defined as follows:&#xD;
&#xD;
               1. Unstable angina and/or congestive heart failure requiring hospitalization&#xD;
&#xD;
               2. Transmural myocardial infarction within the last 6 months&#xD;
&#xD;
               3. Acute bacterial or fungal infection requiring intravenous antibiotics at&#xD;
                  initiation of Radiation Therapy (XRT)/Temozolomide (TMZ)&#xD;
&#xD;
               4. Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy at initiation of XRT/TMZ&#xD;
                  for newly diagnosed patients or at initiation of dose-intensified (DI) TMZ for&#xD;
                  recurrent patients&#xD;
&#xD;
               5. Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects&#xD;
&#xD;
               6. Acquired Immune Deficiency Syndrome (AIDS) based upon current Centers for Disease&#xD;
                  Control and Prevention (CDC) definition. The need to exclude patients with AIDS&#xD;
                  from this protocol is necessary because the treatments involved in this protocol&#xD;
                  may be significantly immunosuppressive&#xD;
&#xD;
               7. Patients with autoimmune disease requiring medical management with&#xD;
                  immunosuppressant(s)&#xD;
&#xD;
               8. Major medical illnesses or psychiatric impairments that, in the investigator's&#xD;
                  opinion, will prevent administration or completion of protocol therapy&#xD;
&#xD;
               9. Active connective tissue disorders such as lupus or scleroderma that, in the&#xD;
                  investigator's opinion, place the patient at high risk for radiation toxicity&#xD;
&#xD;
          6. Pregnant or lactating women&#xD;
&#xD;
          7. Prior allergy to TMZ, GM-CSF, gadolinium (Gd), or Td&#xD;
&#xD;
          8. Prior history of brachial neuritis or Guillain-Barré syndrome&#xD;
&#xD;
          9. Patients treated on any other therapeutic clinical protocols within 30 days prior to&#xD;
             study entry&#xD;
&#xD;
         10. Patients receiving &gt; 0.1mg/kg or 4mg/day dexamethasone or equivalent&#xD;
&#xD;
        10. For recurrent patients only: Patients who have not recovered from the toxic effects of&#xD;
        prior chemo- and/or radiation therapy. Guidelines for this recovery period are dependent&#xD;
        upon the specific therapeutic agent being used:&#xD;
&#xD;
          1. Patients who have received chemotherapy or bevacizumab ≤ 4 weeks [except for&#xD;
             nitrosourea (6 weeks) or metronomic dosed chemotherapy such as daily etoposide or&#xD;
             cyclophosphamide (1 week)] prior to starting the study drug unless patients have&#xD;
             recovered from the side effects of such therapy. If the patient was receiving&#xD;
             bevacizumab at the time of enrollment, the treating oncologist has the discretion of&#xD;
             administering and adjusting bevacizumab 10 mg/kg every 14 days.&#xD;
&#xD;
          2. Patients who have received immunotherapy ≤ 4 weeks prior to starting the study drug&#xD;
             unless patients have recovered from the side effects of such therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Landi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://tischbraintumorcenter.duke.edu</url>
    <description>The Preston Robert Tisch Brain Tumor Center at Duke</description>
  </link>
  <link>
    <url>https://tischbraintumorcenter.duke.edu/pediatrics</url>
    <description>The Preston Robert Tisch Brain Tumor Center at Duke Pediatric Program</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <results_first_submitted>November 30, 2020</results_first_submitted>
  <results_first_submitted_qc>January 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 28, 2021</results_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Gary Archer Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>glioblastoma</keyword>
  <keyword>medulloblastoma</keyword>
  <keyword>glioma</keyword>
  <keyword>pediatric</keyword>
  <keyword>recurrent</keyword>
  <keyword>newly diagnosed</keyword>
  <keyword>Pro00092868</keyword>
  <keyword>Landi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03615404/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients were enrolled at a single institution, Duke University Medical Center.</recruitment_details>
      <pre_assignment_details>All patients were enrolled into one cohort; no randomization occurred.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CMV-DCs With GM-CSF and Td (Tetanus Toxoid)</title>
          <description>CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>vaccine did not pass quality assurance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CMV-DCs With GM-CSF and Td (Tetanus Toxoid)</title>
          <description>CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients for Whom 3 or More Vaccines Can be Made</title>
        <description>Percentage of patients for whom three or more vaccines can be generated from the pre-treatment leukapheresis</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CMV-DCs With GM-CSF and Td (Tetanus Toxoid)</title>
            <description>CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients for Whom 3 or More Vaccines Can be Made</title>
          <description>Percentage of patients for whom three or more vaccines can be generated from the pre-treatment leukapheresis</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Experience Unacceptable Toxicity</title>
        <description>Percentage of patients who experience unacceptable toxicity from CMV-DC administration</description>
        <time_frame>1 year</time_frame>
        <population>One eligible patient had a leukapheresis (evaluable for feasibility), but was withdrawn from the study due to clinical decline prior to receiving any treatment (not evaluable for safety).</population>
        <group_list>
          <group group_id="O1">
            <title>CMV-DCs With GM-CSF and Td (Tetanus Toxoid)</title>
            <description>CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Experience Unacceptable Toxicity</title>
          <description>Percentage of patients who experience unacceptable toxicity from CMV-DC administration</description>
          <population>One eligible patient had a leukapheresis (evaluable for feasibility), but was withdrawn from the study due to clinical decline prior to receiving any treatment (not evaluable for safety).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years from study registration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CMV-DCs With GM-CSF and Td (Tetanus Toxoid)</title>
          <description>CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle weakness left-sided</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Muscle weakness right-sided</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pyramidal tract syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-0000</phone>
      <email>pedsneuronc@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

